modelN05BA06

Diagram of N05BA06

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:Lorazepam
ATC code:N05BA06
route:oral
compartments:1
dosage:2mg
volume of distribution:1.3L
clearance:1.1mL/min/kg
other parameters in model implementation

Lorazepam is a short-acting benzodiazepine used primarily to treat anxiety disorders, insomnia, status epilepticus, and as premedication for anesthesia. It has anxiolytic, sedative, anticonvulsant, and muscle relaxant properties. Lorazepam is widely approved and still clinically used today.

Pharmacokinetics

Pharmacokinetic parameters derived from healthy adult volunteers after a single oral dose.

References

  1. Lebrun-Vignes, B, et al., & Chosidow, O (2001). Clinical pharmacokinetics of mizolastine. Clinical pharmacokinetics 40(7) 501–507. DOI:10.2165/00003088-200140070-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11510627

  2. Fleishaker, JC (2000). Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clinical pharmacokinetics 39(6) 413–427. DOI:10.2165/00003088-200039060-00003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11192474

  3. Stephen, LJ (2003). Drug treatment of epilepsy in elderly people: focus on valproic Acid. Drugs & aging 20(2) 141–152. DOI:10.2165/00002512-200320020-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12534314

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)